{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T15:10:02Z","timestamp":1744038602029,"version":"3.40.3"},"reference-count":32,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Chronic kidney disease (CKD) is a heterogeneous group of disorders characterised by abnormalities in kidney structure or function, present for at least 3 months. Renin\u2013angiotensin system (RAS) inhibitors are established treatments in the management of CKD, reducing the risk of adverse kidney and cardiovascular events. Despite an extensive evidence base and decades of clinical experience, they remain underused, underdosed and frequently discontinued due to concerns about changes in kidney function and hyperkalaemia. In this article, we provide an overview of initiating RAS inhibitors in adults with CKD, highlight current guideline recommendations and offer a practical approach to dealing with the challenges associated with their use.<\/jats:p>","DOI":"10.1136\/dtb.2023.000052","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T11:52:24Z","timestamp":1743594744000},"page":"54-58","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Initiating renin\u2013angiotensin system inhibitors in chronic kidney disease"],"prefix":"10.1136","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-3782","authenticated-orcid":false,"given":"Anna Katharina","family":"Forbes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugh","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2025040707152138000_63.4.54.1","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.73"},{"key":"2025040707152138000_63.4.54.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd873"},{"key":"2025040707152138000_63.4.54.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.10.011"},{"key":"2025040707152138000_63.4.54.4","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","volume":"2006","author":"Strippoli","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2025040707152138000_63.4.54.5","unstructured":"National Institute for Health and Care Excellence . Acute coronary syndromes (NG185) [online]. 2020. Available: https:\/\/www.nice.org.uk\/guidance\/ng185 [Accessed 19 Feb 2025]."},{"key":"2025040707152138000_63.4.54.6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025040707152138000_63.4.54.7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney Int"},{"key":"2025040707152138000_63.4.54.8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07821109"},{"key":"2025040707152138000_63.4.54.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00496-4"},{"key":"2025040707152138000_63.4.54.10","doi-asserted-by":"crossref","first-page":"824095","DOI":"10.3389\/fcvm.2022.824095","article-title":"RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study","volume":"9","author":"Riccio","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025040707152138000_63.4.54.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213192","article-title":"Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study","volume":"14","author":"Jun","year":"2019","journal-title":"PLoS One"},{"key":"2025040707152138000_63.4.54.12","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.79"},{"key":"2025040707152138000_63.4.54.13","unstructured":"National Institute for Health and Care Excellence . Chronic kidney disease: assessment and management (NG203) [online]. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng203 [Accessed 19 Feb 2025]."},{"key":"2025040707152138000_63.4.54.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.11.003"},{"key":"2025040707152138000_63.4.54.15","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480"},{"key":"2025040707152138000_63.4.54.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054602"},{"key":"2025040707152138000_63.4.54.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.08.012"},{"key":"2025040707152138000_63.4.54.18","doi-asserted-by":"publisher","DOI":"10.1016\/J.KINT.2023.10.018"},{"key":"2025040707152138000_63.4.54.19","unstructured":"National Institute for Health and Care Excellence . Chronic heart failure in adults: diagnosis and management (NG106) [online]. 2018. Available: https:\/\/www.nice.org.uk\/guidance\/ng106 [Accessed 19 Feb 2025]."},{"key":"2025040707152138000_63.4.54.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"2025040707152138000_63.4.54.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"2025040707152138000_63.4.54.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"2025040707152138000_63.4.54.23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7326\/0003-4819-137-4-200208200-00026","article-title":"Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease","volume":"137","author":"Jafar","year":"2002","journal-title":"Ann Intern Med"},{"key":"2025040707152138000_63.4.54.24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41440-018-0116-3","article-title":"Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Mishima","year":"2019","journal-title":"Hypertens Res"},{"key":"2025040707152138000_63.4.54.25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp511"},{"key":"2025040707152138000_63.4.54.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210639"},{"key":"2025040707152138000_63.4.54.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62459-4"},{"key":"2025040707152138000_63.4.54.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303154"},{"key":"2025040707152138000_63.4.54.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc081065"},{"key":"2025040707152138000_63.4.54.30","unstructured":"Think Kidneys, The Renal Association, The British Society for Heart Failure . Changes in kidney function and serum potassium during ACEI\/ARB\/diuretic treatment in primary care [online]. 2017. Available: https:\/\/www.thinkkidneys.nhs.uk\/aki\/wp-content\/uploads\/sites\/2\/2017\/10\/Changes-in-Kidney-Function-FINAL.pdf [Accessed 19 Feb 2025]."},{"key":"2025040707152138000_63.4.54.31","unstructured":"National Institute for Health and Care Excellence . Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599) [online]. 2022. Available: https:\/\/www.nice.org.uk\/guidance\/ta599 [Accessed 19 Feb 2025]."},{"key":"2025040707152138000_63.4.54.32","unstructured":"National Institute for Health and Care Excellence . Patiromer for treating hyperkalaemia (TA623) [online]. 2020. Available: https:\/\/www.nice.org.uk\/guidance\/TA623 [Accessed 19 Feb 2025]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2023.000052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T14:36:17Z","timestamp":1744036577000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2023.000052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,2]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/dtb.2023.000052"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2023.000052","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}